STOCKHOLM, Feb. 21, 2025 /PRNewswire/ —
FOURTH QUARTER (OCTOBER – DECEMBER 2024)
TWELVE MONTHS (JANUARY – DECEMBER 2024)
SIGNIFICANT EVENTS DURING THE FOURTH QUARTER
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, CEO, Tel: +46 8 510 530 00, e-mail: johan.lof@raysearchlabs.com
Nina Grönberg, CFO, Tel: +46 8 510 530 00, e-mail: nina.gronberg@raysearchlabs.com
The information contained in this year-end report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 21, 2025, at 7:45 a.m.
WEBCAST
CEO Johan Löf and CFO Nina Grönberg will present RaySearch’s year-end report for January-December 2024 at a webcast to be held in English on Friday, February 21, 2025, at 10:00-10:30 a.m. CET.
Link to webcast: RaySearch Year-end report 2024
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/raysearch-laboratories/r/year-end-report-2024,c4109202
The following files are available for download:
|
RaySearch Year-end report 2024 |
SOURCE RaySearch Laboratories
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…